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Abstract
Background: Thanks to the advances in care, pregnancy is 
now attainable for the majority of young female CKD pa-
tients, although it is still a high-risk endeavor. Clinical deci-
sion-making in these cases is impacted by a myriad of fac-
tors, making (pre)pregnancy counseling a complex process. 
The complexities, further impacted by limited data and un-
known risks regarding outcome, can cause discussions when 
deciding on the best care for a specific patient. Objectives: 
In this article, we provide an overview of the considerations 
and dilemmas we encounter in preconception counseling 
and offer our perspective on how to deal with them in daily 
clinical practice. Methods: The main topics we discuss in our 
counseling are (1) the high risk of pregnancy complications, 
(2) the risk of permanent CKD deterioration due to pregnan-
cy and subsequent decreased life expectancy, (3) appropri-
ate changes in renal medication, and (4) assisted reproduc-
tion, genetic testing, and prenatal or preimplantation genet-
ic diagnostics. Results and Conclusions: In our clinic, we 
openly address moral dilemmas arising in clinical practice in 
pregnancy and CKD, both within the physician team and 
with the patient. We do this by ensuring an interpretive phy-
sician-patient interaction and shared decision-making, de-
liberating in a multidisciplinary setting and, if needed, with 
input from an expert committee. © 2020 The Author(s)
Published by S. Karger AG, Basel
Background
Pregnancy is now attainable for a majority of young 
female CKD patients, although it is still considered high 
risk [1–3]. We experience in our tertiary counseling and 
care center that clinical decision-making in advanced 
CKD and pregnancy is impacted by a myriad of factors.
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An important aspect of (pre)pregnancy care in ad-
vanced CKD is overlooked in the literature, namely, that 
the counseling itself can be a complex process. Limited 
data and unknown risks regarding the outcome, as well as 
differences in risk perception, can make providing the 
(prepregnancy) care needed to ensure a good outcome 
challenging [1].
Methods
We aim to shed light on the clinical practice considerations we 
encounter, providing our perspective on how to deal with deci-
sion-making in daily practice. We do this by discussing the 4 main 
preconception counseling topics that we find can lead to discus-
sions on the best care for a specific patient in our tertiary clinic: (1) 
the high risk of pregnancy complications, (2) the risk of permanent 
CKD deterioration due to pregnancy and subsequent shortened 
life expectancy, (3) changes in renal medication needed in preg-
nancy, and (4) assisted reproduction, genetic testing, and prenatal 
or preimplantation genetic diagnostics (PGD). Additionally, we 
reflect on how we deal with the clinical practice dilemmas we en-
counter in our clinics, to hopefully contribute to a broader discus-
sion on the best prepregnancy care for CKD patients.
Results
Increased Prevalence of Pregnancy Complications in 
CKD
Although data are limited, and often conflicting, over-
all studies have shown increased risks of pre-eclampsia 
(odds ratio [OR] 7–14), caesarean section (OR 2–3), pre-
maturity (OR 3–9), low birthweight (OR 2–6), and need 
for admittance to a neonatal intensive care unit (NICU) 
[4]. As displayed in Figure 1, absolute risks of an adverse 
outcome depend on the CKD stage and whether the pa-
tient is on dialysis or is posttransplant [5–7]. For example, 
for patients with advanced CKD, the pre-eclampsia rate 
is ~50%, caesarean section ~70%, prematurity ~90%, low 
birthweight ~50%, and need for NICU admission ~70% 
[1, 5, 8, 9]. One should note that the definition of (super-
imposed) pre-eclampsia varies between publications, and 
the ~50% should, therefore, be interpreted with caution. 
Overall, fetal complications could lead to neurodevelop-
mental delay for the child, albeit with the improvement 
in neonatal care, many premature babies can lead normal 
lives [10].
As the chance of complications significantly increases 
with advancement in CKD stage (Fig.  1), ideally one 
would discuss planning a pregnancy while the patient is 
still in CKD stages 1–3 and risks are relatively low [5]. 
Risks increase once the patient is in CKD stage 4 or 5 or 
on dialysis [5–7, 11]. Therefore, one could decide to post-
pone a pregnancy until after a kidney transplant. Decid-
ing to postpone is not a clear-cut decision and depends 
on, among others, the length of the transplantation pro-
cess, the risk of suboptimal kidney function posttrans-
plant (which cannot be estimated beforehand), and the 
impact of a pregnancy on the graft.
Finally, although attainable with intensive dialysis 
schedules (e.g., nocturnal hemodialysis for 42 h a week), 
pregnancy is most high risk in dialysis patients [6, 7, 11]. 
Patients and physicians may face a dilemma in cases 
where not harming the mother might harm the (future) 
fetus. This dilemma arises in cases where waiting until 
after a transplant is not preferable, due to maternal age or 
long waiting lists, and one has to decide whether the fetal 
complications of a pregnancy on intensive dialysis can be 
accepted.
Risk of Permanent Renal Function Deterioration due 
to Pregnancy and Limitations to Life Expectancy
Next to the obstetric complications, pregnancy leads 
to a permanent deterioration of renal function in 6–31% 
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Fig. 1. Illustrative figure showing that the prevalence of maternal 
and fetal pregnancy complications (low birthweight, preterm de-
livery, need for NICU, and new-onset maternal hypertension) in-
creases with advancement in CKD stage. Though data are limited, 
evidence shows that in advanced stages of CKD (intensive and 
nocturnal) dialysis risks are high, which decrease after a kidney 
transplant. Therefore, adequate timing of a pregnancy is vital. Data 
derived from *Piccoli et al. [5], #Hladunewich et al. [7], and ‡Desh-
pande et al. [6].




complex in etiology, although the higher filtration rate 
needed in pregnancy likely plays a role [4, 5, 12]. A CKD-
shift means that some stage 4–5 patients may need to start 
dialysis during or in the years after pregnancy, which they 
otherwise might not have to.
Even without a CKD-shift, life expectancy in patients 
with impaired renal function is significantly shortened; 
women with an eGFR  (estimated glomerular filtration 
rate) of 15–29 have a life expectancy of ~13 years in com-
parison to the healthy population [13]. Thus, the mater-
nal lifespan (or lifespan without renal replacement ther-
apy) may not extend to her future child’s adulthood. A 
poignant example is that of women with a renal trans-
plant, as 12% die within 20 years after delivery (median 6 
years) [14].
The long-term consequences of a CKD-shift show 
that clinical practice decisions in pregnancy and CKD 
do not only span the pregnancy itself, but also the rest of 
the mother’s and child’s life. The poor renal outcome 
and limited life expectancy provide a large burden, 
greatly impacting the quality of life for the mother, part-
ner, and child [15]. As is the case for other chronic dis-
eases, such as heart disease, decisions for child care, as 
they pertain to shortened maternal life expectancy, 
ought to be addressed in the preconception stage [16]. 
Even though maternal survival into the child’s adult-
hood is likely for most cases, comprehensive prepara-
tions with the patient’s partner and extended social net-
work can be useful when adverse outcomes occur [16]. 
Further complicating this topic is that the prognosis of 
CKD patients has steadily increased over the past years, 
a trend luckily likely to continue, making it difficult to 
estimate the quality of life for CKD patients 10–20 years 
from now.
Changes in Renal Medication when Considering 
Pregnancy
Fetal safety of a patient’s current treatment is a factor 
to take into account. Within the large branches of CKD 
treatment (antihypertensive, immunosuppressive, and 
biological drugs), there are various safe drugs [1]. Never-
theless, many immunosuppressive drugs (including my-
cophenolate) are contraindicated in pregnancy because 
of teratogenicity and first-trimester losses and should, 
therefore, be discontinued timely [1, 17].
The considerations regarding maternal treatment sur-
round whether it is advisable to discontinue certain drugs 
because of teratogenicity or insufficient safety data, while 
discontinuation could cause adverse maternal renal dis-
ease outcomes (especially posttransplant). Additionally, 
the unknown fetal side effects of certain drugs can render 
the decision even more complex, as one does not know if 
discontinuing a drug important for maternal care will 
even reduce fetal harm [1].
Assisted Reproduction, Genetic Testing, and PGD
During any preconception counseling, a topic to 
consider is the impaired fertility that is common in 
women with advanced CKD [1, 4]. More than healthy 
women, patients may require ovulation induction or as-
sisted reproduction techniques such as in vitro fertiliza-
tion [4].
In assisted reproduction cases, as well as spontaneous 
pregnancies, genetic testing should be considered. Genet-
ic diseases are highly prevalent in the young CKD popula-
tion: ~20% of all ESRD patients presenting before the age 
of 25 have a monogenic kidney disease [18]. A monogen-
ic disease impacts not only the patient, for instance be-
cause different therapies might be indicated, but also her 
offspring, which is at risk of inheriting the kidney disease. 
Although not in all patients the causative genetic defect 
can be found, providing genetic testing opens many ave-
nues for patients [19].
When the causative mutation is known, invasive pre-
natal diagnostic (PND) testing (chorion villus biopsy or 
amniocentesis) can be performed, with a possibility to 
terminate an affected pregnancy [20]. To avoid a need for 
invasive diagnostics (with risk of miscarriage) and termi-
nation, PGD testing has been developed for patients with 
a known monogenic mutation. It brings down the risk of 
passing on the genetic disease to the future child to 1–2% 
[21]. PGD entails performing genetic testing in a single 
cell removed from an in vitro fertilization-embryo and 
only transferring a genetically unaffected embryo to the 
uterus [21]. Furthermore, the physician should realize 
that genetic testing in general and PGD specifically can be 
time consuming (3–24 months). Thus, this is among the 
first topics to discuss with a CKD patient to ensure ade-
quate genetic counseling and care.
Although surrounded with many large- and smaller 
scale good clinical practice considerations, which are be-
yond the scope of this study, the application of PND and 
PGD testing is widely accepted, especially in diseases that 
have an early onset and are severe [22]. Still, in the Neth-
erlands, a (nationwide) committee of expert physicians 
and bioethicists deliberate on each new gene to ensure the 
decision to perform PGD testing is morally sound for that 
specific gene. Whether or not PND or PGD testing can be 
considered depends on its local availability, disease sever-
ity, and patient preference [20, 23].
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Discussion
As stated before, the preconception counseling in 
CKD can be complex, causing discussions on the best 
practice for a specific patient. Below, we provide our per-
spective on how we deal with these discussions and how 
we ensure adequate decision-making in our clinic.
Physician Attitude, Paternalism, and Shared  
Decision-Making
The method of preconception counseling is essential. 
We feel that for adequate decision-making, the patient 
should be fully informed about the risks and potential 
complications of a pregnancy in CKD. Therefore, we ap-
ply a so-called interpretive attitude toward the physician-
patient relationship, which defines the physician as being 
“a counselor (…), supplying relevant information, help-
ing to elucidate values and suggesting what medical inter-
ventions realize these values” [24]. An interpretive atti-
tude in the physician-patient relationship does not allow 
for “hard paternalism” (overriding the preferences of that 
person), yet “soft paternalistic” approaches or directive 
counseling (providing information and even advising 
negatively) could be applied to ensure the patient has all 
the input needed for decision-making [24]. The exchange 
of ideas between a physician and a patient (shared deci-
sion-making) permits the patient an independent choice, 
enhancing her autonomy [25, 26].
Reproductive Autonomy and Nonmaleficence
Reproductive autonomy, the liberty to decide whether 
or not to have children, is the main principle in any dis-
cussion concerning reproduction [27]. Specifically, in ev-
ery decision on pregnancy in CKD, one has to weigh the 
maternal reproductive autonomy against the principle to 
do no harm (nonmaleficence) to the woman or the fetus 
[28, 29].
In principle, we regard the patient’s autonomy as par-
amount in every medical decision. We apply the concept 
of “relational autonomy,” where one includes contextual 
factors, such as the patient’s emotional background, and 
social and financial factors [27]. An important contex-
tual factor is the patient’s partner, who can contribute in 
many ways to the patient’s autonomy and the decisions 
regarding pregnancy. This leads to an open conversation 
whereby the patients feel free to express themselves.
Even though CKD is a risk factor for suboptimal preg-
nancy outcome, in the majority of cases, we feel that the 
desire to not harm the mother or the fetus does not out-
weigh the maternal reproductive autonomy. Underscor-
ing this is the notion that pregnancy is inherently a high-
risk situation, for example, 3–5% of all pregnancies are 
complicated by pre-eclampsia, regardless of maternal co-
morbidity [30]. Therefore, the preconception counseling 
is aimed at the patient understanding the potential risks 
and the physician and patient working together to mini-
mize these risks as much as possible.
Yet, when there is a need for assisted reproduction, we 
find that considerations of not harming the mother and 
fetus are more relevant. That is to say, there is a difference 
between caring for a patient when she becomes pregnant 
naturally and assisting in initiating a pregnancy that puts 
the mother and the fetus at high risks. In such cases, we 
argue that the physician can justifiably act more paternal-
istically, since he or she is actively assisting (instead of 
passively allowing) a situation which one highly suspects 
will harm a future fetus [28, 29].
Multidisciplinary Care
One of the ways we ensure adequate decision-making 
in our tertiary care facility is by providing multidisci-
plinary care. We offer a multidisciplinary outpatient clin-
ic where patients are counseled by a nephrologist and spe-
cialized maternal-fetal medicine specialist. A clinical ge-
neticist specialized in hereditary kidney disease consults 
on genetic testing, PND, and PGD, if applicable. The 
team also confers with fertility specialists, pathologists, 
ethicists, and anesthesiologists to gain insights into tech-
nical care matters related to pregnancy, as well as ethical 
issues that may arise. Furthermore, in cases of assisted 
reproduction or PGD, the team is advised by local and 
national expert committees consisting of physicians and 
medical ethicists.
In conclusion, due to the advances in nephrological, 
fertility, and obstetric care, patients with advanced CKD 
have a myriad of choices regarding pregnancy. They 
should be counseled on the available factual information 
regarding increased pregnancy and renal complications, 
and their long-term impact, including a limited life ex-
pectancy. Furthermore, the options regarding assisted re-
productive technology, genetic testing, PND, and PGD 
should be discussed. However, these topics and the deci-
sions they entail can cause deliberations between physi-
cians, and with the patient, especially since data on these 
issues are limited. We provide our perspective on how to 
deal with these situations, namely, by ensuring an inter-
pretive attitude in the physician-patient relationship and 
shared decision-making, additionally deliberating on 
clinical practice dilemmas in a multidisciplinary setting 
and, if needed, with input from an expert committee.
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